Loading…
Loading…
The iShares U.S. Healthcare ETF is designed to mirror the investment performance of a benchmark index that consists of stocks from American companies within the healthcare industry.
Is IYH's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
The iShares U.S. Healthcare ETF (IYH) offers a broader portfolio with a lower expense ratio than the Invesco Pharmaceuticals ETF (PJP). PJP has delivered significantly higher total returns over the past year.
iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries significantly greater historical price volatility iShares U.S. Healthcare ETF offers a higher dividend yield and lower five-year maximum drawdown for income-focused investors
Stretched tech valuations are reviving AI bubble fears. These ETFs can help navigate the uncertainty.
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund launched on June 12, 2000.